This site is intended for healthcare professionals

Ridgeback Biotherapeutics announces the launch of two phase II clinical trials to test the efficacy of EIDD 2801 as an anti-viral treatment for COVID-19.Merck Inc.

Read time: 1 mins
Last updated:23th Jun 2020
Published:21th Jun 2020
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register free for full access to